Compare ABVX & MOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABVX | MOH |
|---|---|---|
| Founded | 2013 | 1980 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.9B |
| IPO Year | N/A | 2003 |
| Metric | ABVX | MOH |
|---|---|---|
| Price | $114.15 | $184.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 13 |
| Target Price | $118.33 | ★ $210.92 |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 08-11-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 16.24 |
| Revenue | $6,231,374.00 | ★ $42,842,000,000.00 |
| Revenue This Year | $6.80 | $15.41 |
| Revenue Next Year | N/A | $4.27 |
| P/E Ratio | ★ N/A | $10.86 |
| Revenue Growth | N/A | ★ 14.11 |
| 52 Week Low | $4.77 | $133.40 |
| 52 Week High | $148.83 | $359.97 |
| Indicator | ABVX | MOH |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 69.07 |
| Support Level | $116.20 | $176.24 |
| Resistance Level | $129.56 | $188.55 |
| Average True Range (ATR) | 7.87 | 5.49 |
| MACD | -2.47 | 1.62 |
| Stochastic Oscillator | 15.05 | 84.60 |
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Molina provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in just four states—California, New York, Texas, and Washington—account for over half of its enrollees.